Ascletis Pharma (SEHK:1672) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

1672 주식 개요

생명공학 회사인 아스클레티스 파마는 중국 본토에서 의약품의 연구 개발, 제조, 마케팅 및 판매에 종사하는 기업입니다.

1672 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

수익은 향후 3년간 연평균 9.3% 씩 감소할 것으로 예상됩니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Ascletis Pharma Inc. 경쟁사

Brii Biosciences

SEHK:2137

HK$737.1m

Transcenta Holding

SEHK:6628

HK$615.2m

Sunho Biologics

SEHK:2898

HK$1.0b

Essex Bio-Technology

SEHK:1061

HK$1.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Ascletis Pharma
과거 주가
현재 주가	HK$0.92
52주 최고치	HK$2.30
52주 최저치	HK$0.78
베타	0.64
11개월 변경	-20.00%
3개월 변경 사항	-30.30%
1년 변경 사항	-55.12%
33년 변화	-74.23%
5년 변화	-84.46%
IPO 이후 변화	-93.43%

최근 뉴스 및 업데이트

Recent updates

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08

주주 수익률

	1672	HK Biotechs	HK 마켓
7D	10.8%	-4.8%	0.03%
1Y	-55.1%	-36.6%	1.6%

수익률 대 산업: 1672 지난 1년 동안 -34.3 %를 반환한 Hong Kong Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 1672 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 1672's price volatile compared to industry and market?
1672 volatility
1672 Average Weekly Movement	7.8%
Biotechs Industry Average Movement	8.9%
Market Average Movement	6.9%
10% most volatile stocks in HK Market	15.1%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 1672 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 1672 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2013	219	Jinzi Jason Wu	www.ascletis.com

생명공학 회사인 아스클레티스 파마는 중국 본토에서 의약품의 연구 개발, 제조, 마케팅 및 판매에 종사하고 있습니다. 이 회사는 리토나비르 정제, C형 간염 바이러스 치료제인 애클레비어와 가노보를 제공합니다. 또한 만성 B형 간염 및 HIV 기능 치료제인 ASC22, 호흡기 세포융합 바이러스 치료제인 ASC10, COVID-19 치료제인 ASC10 및 ASC11, 비알코올성 지방간염 치료제인 ASC40, ASC41, ASC42, ASC43F FDC, 원발성 담즙성 담관염 치료제인 ASC42를 개발 중입니다.

Ascletis Pharma Inc. 기본 사항 요약

Ascletis Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
1672 기본 통계
시가총액	HK$911.48m
수익(TTM)	-HK$155.41m
수익(TTM)	HK$60.78m

15.3x

P/S 비율

-6.0x

P/E 비율

1672 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
1672 손익 계산서(TTM)
수익	CN¥56.60m
수익 비용	CN¥30.61m
총 이익	CN¥25.99m
기타 비용	CN¥170.71m
수익	-CN¥144.71m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.14
총 마진	45.92%
순이익 마진	-255.70%
부채/자본 비율	0%

1672 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

1672 주식 개요

보상

위험 분석

Ascletis Pharma Inc. 경쟁사

SEHK:2137

HK$737.1m

SEHK:6628

HK$615.2m

SEHK:2898

HK$1.0b

SEHK:1061

HK$1.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Recent updates

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

First half 2023 earnings: EPS exceeds analyst expectations

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Consensus revenue estimates decrease by 19%, EPS upgraded

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

New minor risk - Profitability

Consensus revenue estimates decrease by 22%, EPS upgraded

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2023

Consensus revenue estimates decrease by 12%

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2023

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Insufficient new directors

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Consensus revenue estimates fall by 19%

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

Consensus revenue estimates fall by 13%

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021)

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors